Literature DB >> 6681888

A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults.

R H Mattson, J A Cramer, A V Delgado Escueta, D B Smith, J F Collins.   

Abstract

The design for the comparative evaluation of the efficacy and toxicity of phenobarbital, phenytoin, primidone, and carbamazepine is outlined. A double-blind prospective study of a sufficient number of patients can determine the optimum drug to use initially for partial and generalized tonic-clonic seizures in adults. The rationale for methods defines the major parameters that should be addressed in order to determine optimum drug for longterm seizure therapy. Major problems in the function of such a project include aspects of sample size attainment, screening/recruitment, non-drug-related losses, and adjustments to the ongoing protocol. The design, with modifications, can be used to study other antiepileptic drugs and other types of seizures.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6681888     DOI: 10.1212/wnl.33.3_suppl_1.14

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  [Stem cell transplantation for multiple sclerosis. Hamburg experiences and state of international research].

Authors:  J-P Stellmann; K H Stürner; F Ufer; S Havemeister; J Pöttgen; F Ayuk Ayuketang; N Kröger; M A Friese; C Heesen
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

2.  The contribution of the measurement of seizure severity to quality of life research.

Authors:  D Smith; G A Baker; A Jacoby; D W Chadwick
Journal:  Qual Life Res       Date:  1995-04       Impact factor: 4.147

3.  Side-effects of drugs in epileptic patients.

Authors:  A Keyser; Y A Hekster; E Termond; A Theeuwes; M Schaap; H T Rwiza
Journal:  Pharm Weekbl Sci       Date:  1990-08-24

4.  Ecological validity of walking capacity tests in multiple sclerosis.

Authors:  J P Stellmann; A Neuhaus; N Götze; S Briken; C Lederer; M Schimpl; C Heesen; M Daumer
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.